IAMH
NTLA icon

IvyRock Asset Management (HK)’s Intellia Therapeutics NTLA Stock Holding History

IvyRock Asset Management (HK)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Sell
10,000
-9,830
-50% -$138K 0.1% 22
2026
Q1 		$254K Buy
19,830
+500
+3% +$6.37K 0.14% 20
2025
Q4 		$174K Buy
19,330
+5,000
+35% +$68.8K 0.09% 21
2025
Q3 		$247K Buy
+14,330
New +$176K 0.11% 15

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

IvyRock Asset Management (HK)'s NTLA Position: Q2 2026 in Review

IvyRock Asset Management (HK) reduced its Intellia Therapeutics (NTLA) stake by 50% in Q2 2026, selling an estimated $138K and leaving 10,000 shares worth $169K. The position accounts for 0.1% of the portfolio, ranked #22.

IvyRock Asset Management (HK) first reported a position in NTLA in Q3 2025 and has held it in 4 quarters since. The position peaked at $254K in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • IvyRock Asset Management (HK) held 10,000 shares of Intellia Therapeutics worth $169K as of Q2 2026.
  • IvyRock Asset Management (HK) sold 9,830 Intellia Therapeutics shares in Q2 2026, an estimated $138K.
  • Intellia Therapeutics made up 0.1% of IvyRock Asset Management (HK)'s portfolio in Q2 2026, its #22 holding.
  • IvyRock Asset Management (HK) first reported a position in Intellia Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • IvyRock Asset Management (HK)'s Intellia Therapeutics position peaked at $254K in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on IvyRock Asset Management (HK)'s 13F filing for Q2 2026, filed 4 Aug 2026.